{Reference Type}: Journal Article
{Title}: Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause.
{Author}: Stute P;Bertschy S;Birkhaeuser M;Bitzer J;Ging A;Raggi A;Steimann S;Stute V;
{Journal}: Climacteric
{Volume}: 25
{Issue}: 3
{Year}: 06 2022
{Factor}: 3.024
{DOI}: 10.1080/13697137.2021.2008894
{Abstract}: Genitourinary syndrome of menopause (GSM) has a significantly negative impact on affected women's lives. However, despite the increasing number of GSM treatment options (e.g. non-hormonal vaginal products, vaginal hormones [estrogens], dehydroepiandrosterone [DHEA; prasterone], vaginal laser therapy, oral ospemifene), many women remain untreated. The goal of the Swiss interdisciplinary GSM consensus meeting was to develop tools for GSM management in daily practice: a GSM management algorithm (personalized medicine); a communication tool for vaginal DHEA (drug facts box); and a communication tool for understanding regulatory authorities and the discrepancy between scientific data and package inserts. The acceptance and applicability of such tools will be further investigated.